Yesterday, March 10, 2016, 72 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $0.50 to $3,930,180.00.

Highlighted Stocks Traded by Insiders:

Stemline Therapeutics (STML) - FREE Research Report

Gionco David, who is Chief Accounting Officer at Stemline Therapeutics, sold 1,148 shares at $5.32 on March 10, 2016. Following this transaction, the Chief Accounting Officer owned 106,467 shares meaning that the stake was reduced by 1.07% with the 1,148-share transaction.

Bergstein Ivan, who is Chief Executive Officer at Stemline Therapeutics, sold 5,537 shares at $5.34 on March 10, 2016. Following this transaction, the Chief Executive Officer owned 1.8 million shares meaning that the stake was reduced by 0.3% with the 5,537-share transaction.

Hoberman Kenneth, who is Chief Operating Officer at Stemline Therapeutics, sold 2,412 shares at $5.34 on March 10, 2016. Following this transaction, the Chief Operating Officer owned 297,392 shares meaning that the stake was reduced by 0.8% with the 2,412-share transaction.

The shares most recently traded at $5.38, up $0.04, or 0.74% since the insider transaction. Historical insider transactions for Stemline Therapeutics go as follows:

  • 4-Week # shares bought: 2,000
  • 4-Week # shares sold: 4,747
  • 12-Week # shares bought: 2,000
  • 12-Week # shares sold: 7,964
  • 24-Week # shares bought: 2,000
  • 24-Week # shares sold: 20,199

The average volume for Stemline Therapeutics has been 105,800 shares per day over the past 30 days. Stemline Therapeutics has a market cap of $94.9 million and is part of the health care sector and drugs industry. Shares are down 19.81% year-to-date as of the close of trading on Thursday.

Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary therapeutics for cancer stem cells and bulk tumors in the United States. Currently, there are 6 analysts who rate Stemline Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on STML - FREE

TheStreet Quant Ratings

rates Stemline Therapeutics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

Stemline Therapeutics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Ares Capital (ARCC) - FREE Research Report

Lem Scott C, who is CAO, VP & Treasurer at Ares Capital, bought 1,800 shares at $14.00 on March 10, 2016. Following this transaction, the CAO, VP & Treasurer owned 16,287 shares meaning that the stake was boosted by 12.42% with the 1,800-share transaction.

The shares most recently traded at $13.76, down $0.24, or 1.74% since the insider transaction. Historical insider transactions for Ares Capital go as follows:

  • 4-Week # shares bought: 109,300
  • 12-Week # shares bought: 109,500
  • 24-Week # shares bought: 114,810

The average volume for Ares Capital has been 2.2 million shares per day over the past 30 days. Ares Capital has a market cap of $4.4 billion and is part of the financial sector and financial services industry. Shares are down 1.68% year-to-date as of the close of trading on Thursday.

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. The stock currently has a dividend yield of 10.75%. The company has a P/E ratio of 8.6. Currently, there are 10 analysts who rate Ares Capital a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ARCC - FREE

TheStreet Quant Ratings

rates Ares Capital as a

hold

. Among the primary strengths of the company is its expanding profit margins over time. At the same time, however, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full

Ares Capital Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Patrick Industries (PATK) - FREE Research Report

Rodino Jeff, who is EVP-Sales & COO at Patrick Industries, sold 20,000 shares at $43.94 on March 10, 2016. Following this transaction, the EVP-Sales & COO owned 71,647 shares meaning that the stake was reduced by 21.82% with the 20,000-share transaction.

The shares most recently traded at $43.12, down $0.82, or 1.9% since the insider transaction. Historical insider transactions for Patrick Industries go as follows:

  • 4-Week # shares bought: 9,800
  • 4-Week # shares sold: 40,380
  • 12-Week # shares bought: 9,800
  • 12-Week # shares sold: 40,380
  • 24-Week # shares bought: 18,000
  • 24-Week # shares sold: 40,380

The average volume for Patrick Industries has been 175,100 shares per day over the past 30 days. Patrick Industries has a market cap of $684.0 million and is part of the industrial goods sector and materials & construction industry. Shares are up 0.25% year-to-date as of the close of trading on Thursday.

Patrick Industries, Inc. manufactures and distributes building products and materials for the recreational vehicle, manufactured housing, and industrial markets in ten states. The company has a P/E ratio of 16.2. Currently, there are 2 analysts who rate Patrick Industries a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PATK - FREE

TheStreet Quant Ratings

rates Patrick Industries as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, attractive valuation levels and notable return on equity. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full

Patrick Industries Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.